Sana Biotechnology

### Executive Summary Sana Biotechnology raised $309.8M in a Regulation D private placement, reflecting significant investor appetite for synthetic biology and intracellular mRNA delivery platforms. The first sale date was October 12, 2025, and the filing was made with the SEC under accession 0001702600-24-20127. Related persons include Lockheed Martin Ventures and Bessemer Venture Partners, suggesting strong institutional interest bridging defense and biotech. ### Investor Edge Watch for any subsequent Form D/A amendments, which could reveal additional investors or a capital increase. Also monitor Lockheed Martin Ventures for related press releases or joint development agreements, as their presence often precedes government contracts. ### Sector capital positioning The $309.8M raise signals a capital inflow into synthetic biology and mRNA delivery, a sector that continues to attract large private rounds. Government-linked investors like Lockheed Martin Ventures indicate potential dual-use or national security applications. ### Convergence Signals No explicit public signals (patents, contracts, legislation) are referenced in the filing. However, Lockheed Martin Ventures' involvement hints at potential convergence with defense-related biotech or advanced therapeutics for field applications. Further investigation of Lockheed Martin's public portfolio and recent DoD biotech solicitations would be warranted. ### Key Takeaways - Sana Biotechnology raised $309.8M in a private Reg D round, a large amount for synthetic biology & mRNA delivery. - Lockheed Martin Ventures and Bessemer Venture Partners are listed as related persons, indicating strategic and institutional backing. - No public ticker; this is a private placement, so no directly comparable public stock to trade on this signal. ### Risk Indicators & Flags Form Type D is an initial notice; no amendments filed yet. The $309.8M round is unusually large for a Form D, which could indicate a late-stage private round or a large syndicate. No regulatory concerns noted. The involvement of a defense investor (Lockheed Martin Ventures) may invite additional scrutiny or restrictions if the technology has dual-use applications. ### Verification & References Verify filing details at SEC EDGAR: https://www.sec.gov/cgi-bin/browse-edgar?company=Sana%20Biotechnology&type=D&action=getcompany using accession number 0001702600-24-20127. The amount $309.8M and first sale date 2025-10-12 are directly from the filing. Related persons list includes Lockheed Martin Ventures and Bessemer Venture Partners—confirm their SEC officer/director roles via EDGAR ownership filings.